SGNB6A-001: what clinicians are saying
sigvotatug vedotin (SGN-B6A); sigvotatug vedotin (SGN-B6A) plus pembrolizumab plus platinum-based chemotherapy in advanced solid tumors · NCT04389632 ↗ · Phase 1 · Seagen, a wholly owned subsidiary of Pfizer
A speaker questions the credibility of SGNB6A-001’s subgroup evidence, citing repeated patient subdivisions, but the criticism does not establish improper analysis. For the nonsquamous, taxane-naive subgroup, prespecification and the alleged discrepancy between abstract and presentation remain unresolved. The speaker’s clinical role could not be confirmed. The sources place these phase I results in NSCLC at ASCO 2024.
Created with AI · how we check it
- edition 1
- commentary checked Nov 21, 2026
- 3 verified statements
2 findings, and what sits behind each
01. SGNB6A-001: a speaker questions subgrouping, reporting and PFS precision
No named clinician · accounts and unnamed speakers · 2 statements from 1 speaker in 1 source · 2 passages
Limitations recorded: 3.
Draws on: Population and setting, Secondary endpoints, Design and conduct.
02. SGNB6A-001: why a speaker questions a phase III launch on subgroup data
No named clinician · accounts and unnamed speakers · 2 statements from 1 speaker in 1 source · 1 passage
Limitations recorded: 1.
Draws on: Secondary endpoints, Population and setting.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 2
No named clinician · accounts and unnamed speakers
SGNB6A-001: a speaker questions subgrouping, reporting and PFS precision
2 statements from 1 speaker in 1 source
The one named speaker in this finding holds this view
- 2
- statements
- 2
- passages
- 1
- source
- 1
- speaker
What the statements areViews 1Questions and uncertainty 1Clinical experience 0Comparisons 0Restated results and context 0Statement-to-passage links (a passage can back several statements)Supporting a statement 2Giving context 0Recorded with the findingLimitations: 3
1 post or article
Draws on: Population and setting, Secondary endpoints, Design and conduct.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
Abbreviations (8)
AE, adverse event; ASCO, American Society of Clinical Oncology; DLT, dose-limiting toxicity; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; NSCLC, non-small cell lung cancer; PFS, progression-free survival.
The full SGNB6A-001 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
By the numbers
- 17commentary sources screened
- 1source cited by verified statements
- 2named in screened sources
- 1speaker cited in the report
- 0cited speakers with a verified identity
0 cited clinicians, speakers with a confirmed clinical role, of them 0 physicians.
- 3verified statements, each linked to its source
- 0of them from speakers with a confirmed clinical role
- 2findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 2 | Titles free |
| Detailed analysis | 3 sections | Paid |
| Verified statements with short source quotes and links | 3 | Paid |
| Who said each statement: the cited speakers | 1 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 0 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 10 | Free |
| Sources with links | 1 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
5 discussed · 5 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Number of participants with adverse events (AEs)no commentary found | 0 | 0 |
| Primary endpoint: Number of patients with laboratory abnormalitiesno commentary found | 0 | 0 |
| Primary endpoint: Number of participants with dose-limiting toxicities (DLTs)no commentary found | 0 | 0 |
| Secondary endpoints | 1 | 1 |
| Population and setting | 2 | 1 |
| The comparisonThe registered arms and what clinicians said about how they compare.no commentary found | 0 | 0 |
| Safety and tolerabilityno commentary found | 0 | 0 |
| Design and conduct | 1 | 1 |
| Abstract–ASCO24 presentation consistency | 1 | 1 |
| Evidence threshold for phase III development | 2 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
3 verified statements from 1 cited source. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Posts · 3 statements · 100% | ||||
| X threads | 3 | 1 | 15 | |
| Bluesky threads | 0 | 0 | 2 | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 7 / quarter
- Screened window
- Oct 20, 2023 → Nov 13, 2026
- Cited window
- Jun 1, 2024 → Jun 1, 2024
- Retrieved
- Nov 21, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Registry
- NCT04389632
- Study IDs
- SGNB6A-001 · C5751001 (Alias Study Number) · 2023-508469-34-00 (CTIS (EU))
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Design
- Phase 1 · Interventional, sequential
- Status
- Recruiting
- Enrollment
- 1,006 estimated
- Registered
- 2020-05-15
- Start
- 2020-06-08 actual
- Primary completion
- 2027-06-16 estimated
- Primary endpoints
- Number of participants with adverse events (AEs)
- Number of patients with laboratory abnormalities
- Number of participants with dose-limiting toxicities (DLTs)
- Interventions
- 4 registered
More on: Non-small cell lung cancer, Head and neck squamous cell carcinoma, Esophageal squamous cell carcinoma, Esophageal adenocarcinoma, Gastroesophageal adenocarcinoma, Advanced solid tumors, pembrolizumab
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on efficacy and tolerability in lung cancer, including taxane-naive nonsquamous disease.
- 19 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 31 sources about other trials or topics are not included.
- The cited substantive views come from one X account on 1 June 2024 and do not show how widely HCPs share them.
Show all 7 known gaps +Fewer −
- Coverage of public discussion is incomplete: comments without recognizable trial identifiers or trial/drug names, including some transcription variants, may be missing.
- The reviewed posts do not establish whether the subgroup analyses were prespecified, independently reconcile the abstract with the presentation, or provide numerical confidence-interval limits.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 21, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. SGNB6A-001 (NCT04389632): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/sgnb6a-001-nct04389632
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "SGNB6A-001" (NCT04389632), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "sgnb6a-001-nct04389632". If you cannot make requests, read https://www.erudio.com/reports/sgnb6a-001-nct04389632.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT04389632", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT04389632 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/sgnb6a-001-nct04389632.json
curl https://www.erudio.com/reports/sgnb6a-001-nct04389632.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "sgnb6a-001-nct04389632" })release 106161623e8afe602645b571e72a302adf0a9f24a336f7c186362b719275bd46
Questions
How much does the SGNB6A-001 report cost?
This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.
What does the SGNB6A-001 report cover?
3 statements from 1 source (1 post), each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the SGNB6A-001 report?
Its preview, yes: get_report_card({ "slug": "sgnb6a-001-nct04389632" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. Connect your AI client.
How current is the SGNB6A-001 report?
Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.